ALZN · Alzamend Neuro, Inc. · Financials
$1.68
+0.00 (+0.00%)
At close · Sep 9
Going-concern doubt
— flagged Jul 22, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our independent registered public accounting firm has issued a report on our financial statements for the year ended April 30, 2026, that contains an emphasis of a matter paragraph expressing substantial doubt about our ability to continue as a going concern due to insufficient capital for us to fund our operations.”View the 10-K filed Jul 22, 2026
Market Cap
$8.05M
Shares
4.79M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Net Income
-$8.77M
-94.3%
FY2026
Diluted EPS
-$2.63
+76.8%
FY2026
Operating Cash Flow
-$8.07M
-22.8%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | — | — | — | — | $1706 | $13.93K | |
| $3.63M | $1.41M | $6.46M | $7.45M | $5.2M | $1.31M | $1.07M | |
| $5.14M | $3.08M | $3.48M | $7.42M | $7.12M | $3.64M | $3.35M | |
| $8.77M | $4.5M | $9.94M | $14.87M | — | — | — | |
| — | — | — | $14.87M | $12.32M | $4.95M | $4.42M | |
| -$8.77M | -$4.5M | -$9.94M | -$14.87M | -$12.32M | -$4.95M | -$4.42M | |
| $6619 | $18.03K | $10.1K | $7701 | $46.52K | $142.42K | — | |
| $1078 | — | — | — | — | — | — | |
| -$5541 | -$18.03K | -$10.1K | -$7701 | -$42.52K | -$94.68K | $13.93K | |
| -$8.77M | -$4.51M | -$9.95M | -$14.88M | -$12.36M | -$5.05M | -$4.41M | |
| -$8.77M | -$4.51M | -$9.95M | -$14.88M | -$12.36M | -$5.05M | -$4.41M | |
| -$8.77M | -$5.11M | -$9.95M | — | — | — | — | |
| USD/shares | -$2.63 | -$11.32 | -$132.33 | -$206.01 | -$189.00 | — | — |
| USD/shares | -$2.63 | -$11.32 | -$132.33 | -$206.01 | -$189.00 | — | — |
| shares | 3.34M | 450.8K | 74.17K | 72.24K | 66K | 53.81K | 52.78K |
| shares | 3.34M | 450.8K | 74.17K | 72.24K | 66K | 53.81K | 52.78K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.96×
EV/EBIT
—
P/E (TTM)
—
Peer median 1.85×
Peer medians compare against the 190 similar-size Biotechnology companies (of 537 listed).